GLP-1 Agonist Semaglutide Reduces Alcohol Craving and Heavy Drinking in First Randomized Trial

Addiction medicine has three FDA-approved pharmacotherapies for alcohol use disorder: naltrexone, acamprosate, and disulfiram. The field has not gained a new mechanism of action in decades. This trial from Hendershot and colleagues at the University of Toronto is the first prospective randomized evidence that a GLP-1 receptor agonist — the same drug class that reshaped obesity and diabetes treatment — can reduce alcohol craving and consumption. The clinical implications extend far beyond the 48 participants in this study.

What the numbers actually show

The trial was small but carefully designed: double-blind, placebo-controlled, with both laboratory self-administration (the gold standard for human alcohol pharmacotherapy research) and prospective real-world drinking outcomes. Semaglutide was titrated slowly — 0.25 mg/week for four weeks, 0.5 mg for four weeks, then 1.0 mg for one week.

The laboratory findings are striking. In a controlled alcohol self-administration session after eight weeks of treatment, participants on semaglutide consumed significantly less alcohol (beta=-0.48) and achieved lower peak breath alcohol concentrations (beta=-0.46). These are medium-to-large effects by conventional standards. In the real world, semaglutide did not reduce the number of drinking days — people still drank — but when they drank, they drank less (beta=-0.41 for drinks per drinking day). This pattern is clinically coherent: the drug appears to reduce the reinforcing value of alcohol rather than eliminating the behaviour entirely.

The craving reduction (beta=-0.39) is mechanistically important. GLP-1 receptors are expressed in mesolimbic reward circuits — the nucleus accumbens, ventral tegmental area, and amygdala. Preclinical work has demonstrated that GLP-1 agonists reduce dopamine release in these regions. Semaglutide may be dampening the neurobiological salience of alcohol, not just suppressing appetite.

What changes for practitioners

This is a phase 2 proof-of-concept, not a practice-changing trial. Yet. But three things matter right now.

First, many patients with AUD are already taking semaglutide for obesity or type 2 diabetes. If you treat addiction and your patient is on Ozempic or Wegovy, ask about their drinking. You may already be observing this effect without knowing it — the pharmacoepidemiological data from Wang et al. (2024, Nature Communications) showed a 50-56% reduced risk of AUD recurrence in semaglutide users.

Second, the incidental finding on cigarette reduction (beta=-0.10, p=.005) among the smoking subsample suggests the reward-dampening effect is not alcohol-specific. This aligns with emerging data on GLP-1 agonists and substance use disorders broadly.

Third, a phase 3 trial (the SEMALCO trial, NCT registries) is underway in Denmark, specifically testing semaglutide in AUD patients with comorbid obesity. The field is moving fast.